Scarica l'app Stockscreener
14.08
0.43%
0.06
Dopo l'orario di chiusura:
14.08
Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie
(ENTA) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
ENTA stock holds steady as Enanta Pharmaceuticals focuses on antiviral pipeline - AD HOC NEWS
Enanta Pharmaceuticals stock gains after new SEC filing and solid cash position - AD HOC NEWS
Enanta Pharmaceuticals to Participate in September Investor Conferences - Business Wire
Enanta stock holds in the low teens as investors look to recent trial and earnings progress - AD HOC NEWS
Enanta (ENTA) Watch: Finishes 2.59% Up at $13.47 for the Current Session; Boundary Watch: the Price Remains Bounded by the Supplied Support and ResistanceMoney Flow Index - vinanet.vn
Deep Track Capital, LP Trims Enanta Pharmaceuticals Inc (ENTA) S - GuruFocus
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Share Price, ENTA Stock News, ENTA Share Price & Updates - Kalkine
Enanta Pharmaceuticals Announces Q3 Fiscal 2026 Financial Results - Kalkine Media
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline - scanx.trade
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates - NewsBreak: Local News & Alerts
Is Enanta Pharmaceuticals (ENTA) Overvalued After Q3 Earnings Mi - GuruFocus
Enanta Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com - Investing.com Canada
Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss - TradingKey
Enanta Pharma misses Q3 estimates on lower royalty revenue - Investing.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS - marketbeat.com
Enanta Pharmaceuticals reports Q3 loss; revenue $14.4M, cash and securities $211.5M - tradingview.com
Enanta Pharma On Track to File IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select MRGPRX2 Development Candidate, in 2H >ENTA - Moomoo
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - Barchart.com
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 - Business Wire
ENANTA PHARMACEUTICALS ($ENTA) Releases Q3 2026 Earnings - Quiver Quantitative
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Enanta Pharmaceuticals (ENTA) Climbs 3.2% as Shares Test Key Resistance at $14.46Market Profile - dars.gov.et
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(ENTA) Risk Channels and Responsive Allocation - Stock Traders Daily
Enanta Pharmaceuticals (ENTA) Expected to Post Quarterly Earnings on Monday - MarketBeat
Enanta Pharmaceuticals Inc (ENTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ENTA|Enanta Pharmaceuticals Inc|Price:12.780|Chg%:-0.170 - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
Enanta Pharmaceuticals Inc (ENTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
ENTA|Enanta Pharmaceuticals Inc|Price:12.730|Chg%:-0.050 - TradingKey
Enanta Pharmaceuticals (ENTA) Slides to $12.78 as Selling Pressure PersistsKeltner Channel - dars.gov.et
Enanta Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ENTA - TradingView
Enanta Pharmaceuticals (ENTA) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Enanta Pharmaceuticals Inc (ENTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enanta Pharmaceuticals (9EP) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Enanta Was First to File. Pfizer Still Won. The Difference Was One Digit. - JD Supra
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enanta v. Pfizer is Not About a Typo: It is About Possession of the Invention - IPWatchdog.com
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – BX:9EP - TradingView
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
(ENTA) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – SWB:9EP - TradingView
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – DUS:9EP - TradingView
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – DUS:9EP - TradingView
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP - TradingView
Enanta Pharmaceuticals (ENTA) Q2 2026 Earnings: Narrower Loss Surprises Amid Steady Pipeline Progress - dars.gov.et
Enanta Pharmaceuticals outlines its antiviral pipeline. Focus on long-term opportunities for ENTA st - ad-hoc-news.de
Enanta Pharmaceuticals Establishes Flexible At-The-Market Offering - The Globe and Mail
Liquidity Mapping Around (ENTA) Price Events - Stock Traders Daily
Enanta Enters $75 Million At-the-Market Stock Offering Agreement - Moomoo
Federal Circuit Rules Written Description Standard Governs Patent Priority In Enanta Pharmaceuticals v. Pfizer (PFE) - londoninsider.co.uk
Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Federal Circuit Patent Watch: Federal Circuit Clarifies The Skilled Searcher Standard For IPR Estoppel And Holds That District Court Relied On Insufficient Evidence To Apply IPR Estoppel - WilmerHale
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2500 Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2000 Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals (ENTA) Rises 3.64% as Biotech Sector Momentum Buoys SharesBPI Bull Correction - po-news-eg.net
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry - Moomoo
Enanta Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):